The EIF4A2 Knockout K-562 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population featuring targeted disruption of the EIF4A2 gene in the human K-562 chronic myelogenous leukemia (CML) cell line. This loss-of-function model enables detailed investigation of EIF4A2-dependent translation control in a Philadelphia chromosome-positive (BCR-ABL1) hematopoietic background. The polyclonal format provides a heterogeneous pool of edited cells, offering a robust system for studying EIF4A2 function while mitigating clonal selection artifacts. Researchers can employ this product to dissect the molecular mechanisms underlying cap-dependent translation and its dysregulation in leukemogenesis.
The host K-562 cell line was originally derived from a CML patient in blast crisis and harbors the BCR-ABL1 fusion oncogene, which drives constitutive tyrosine kinase activity and aberrant downstream signaling. K-562 cells exhibit hematopoietic progenitor-like characteristics and serve as a widely used model for myeloid leukemia, particularly for studying BCR-ABL-mediated oncogenesis. Their Philadelphia chromosome-positive status makes them especially relevant for examining how oncogenic tyrosine kinase signaling interfaces with the translational machinery. This cellular context provides a clinically pertinent system for evaluating EIF4A2 function in a malignancy characterized by heightened protein synthesis and proliferation.
EIF4A2 encodes an ATP-dependent RNA helicase that is an essential component of the eIF4F translation initiation complex, where it cooperates with eIF4E and eIF4G to unwind secondary structures in the 5?? untranslated regions (UTRs) of mRNAs, thereby facilitating ribosome scanning and translation. Its activity is regulated by upstream signals from mTORC1, which phosphorylates 4E-BPs to relieve inhibition of eIF4E, and is further modulated by interaction partners including PDCD4, eIF4B, and eIF4H. EIF4A2 preferentially unwinds structured 5?? UTRs present in oncogenic transcripts such as MYC, BCL2, and CCND1, linking growth factor and nutrient signaling to the selective translation of pro-survival and cell cycle regulators. Disruption of EIF4A2 impairs the expression of these targets, providing a direct mechanistic link between translation control and leukemic cell fitness.
In the K-562 cellular context, BCR-ABL potently activates mTORC1, resulting in hyperactivation of eIF4F-dependent translation and sustained expression of oncogenic proteins that drive cell proliferation and suppress apoptosis. By knocking out EIF4A2, this cell model attenuates the translational output of key downstream effectors such as MYC and BCL2, mirroring the effects of pharmacologic eIF4A inhibition. This uniquely positions the EIF4A2 Knockout K-562 Polyclonal Cells as a tool for studying resistance mechanisms to BCR-ABL inhibitors, evaluating novel translation-targeted therapeutics, and understanding the integration of oncogenic kinase signaling with the translational apparatus. The model thus holds significant value for both basic leukemia biology and translational oncology research.
This product is suited for a wide range of experimental applications, including functional validation of EIF4A2 in cap-dependent translation using luciferase reporter assays, polysome profiling to assess global translation changes, and RNA-sequencing to identify transcript-specific translational control. Researchers can also employ Western blotting for EIF4A2 and downstream targets, MTT assays to evaluate proliferation, and flow cytometry (Annexin V staining) to quantify apoptotic responses. Additionally, analysis of BCR-ABL signaling via phospho-CrkL immunoblotting enables correlation between translation inhibition and oncogenic kinase activity. These cells facilitate drug target validation for eIF4F complex inhibitors and mechanistic studies of mTOR-driven leukemogenesis. For more information, please contact Ascent Research.
